Somewhat Favorable Media Coverage Somewhat Unlikely to Affect GenMark Diagnostics (GNMK) Share Price

News stories about GenMark Diagnostics (NASDAQ:GNMK) have been trending somewhat positive recently, Accern Sentiment reports. The research firm scores the sentiment of press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. GenMark Diagnostics earned a coverage optimism score of 0.16 on Accern’s scale. Accern also assigned press coverage about the medical equipment provider an impact score of 44.3500403925753 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Several brokerages have commented on GNMK. Bank of America Corporation began coverage on shares of GenMark Diagnostics in a report on Monday, September 18th. They issued a “buy” rating and a $13.00 price objective for the company. Needham & Company LLC reiterated a “buy” rating and set a $15.00 target price on shares of GenMark Diagnostics in a report on Wednesday, October 4th. BTIG Research restated a “buy” rating and issued a $13.00 price objective on shares of GenMark Diagnostics in a report on Thursday, August 31st. Cowen and Company restated an “outperform” rating and issued a $17.00 price objective on shares of GenMark Diagnostics in a report on Wednesday, August 2nd. Finally, Canaccord Genuity restated a “buy” rating on shares of GenMark Diagnostics in a report on Wednesday, September 27th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $14.40.

Shares of GenMark Diagnostics (GNMK) traded down 1.94% during midday trading on Friday, hitting $7.58. 383,489 shares of the stock were exchanged. GenMark Diagnostics has a 12 month low of $7.51 and a 12 month high of $13.67. The stock’s market cap is $414.38 million. The firm’s 50-day moving average is $9.12 and its 200-day moving average is $11.17.

GenMark Diagnostics (NASDAQ:GNMK) last announced its quarterly earnings data on Tuesday, August 1st. The medical equipment provider reported ($0.37) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.32) by ($0.05). GenMark Diagnostics had a negative return on equity of 109.89% and a negative net margin of 111.96%. The firm had revenue of $12.36 million for the quarter, compared to analysts’ expectations of $12.44 million. During the same quarter in the previous year, the company posted ($0.30) EPS. The firm’s quarterly revenue was down 1.2% compared to the same quarter last year. Equities research analysts predict that GenMark Diagnostics will post ($1.07) earnings per share for the current year.

In related news, CFO Scott Mendel sold 2,898 shares of the firm’s stock in a transaction that occurred on Monday, August 21st. The shares were sold at an average price of $9.45, for a total value of $27,386.10. Following the transaction, the chief financial officer now owns 138,096 shares in the company, valued at $1,305,007.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Eric Stier sold 2,750 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $9.60, for a total transaction of $26,400.00. The disclosure for this sale can be found here. Insiders have sold a total of 58,736 shares of company stock worth $544,341 over the last ninety days. 7.50% of the stock is owned by corporate insiders.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright laws. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2017/10/27/genmark-diagnostics-gnmk-earning-somewhat-positive-press-coverage-accern-reports.html.

About GenMark Diagnostics

GenMark Diagnostics, Inc is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology.

Insider Buying and Selling by Quarter for GenMark Diagnostics (NASDAQ:GNMK)

Receive News & Ratings for GenMark Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply